CatalystAlert

Search CatalystAlert

Search for companies, drugs, and catalysts

Search CatalystAlert

Search for companies, drugs, and catalysts

All Catalyst Types

NDA Filings

As of Nov 17, 2026, CatalystAlert tracks 16 upcoming nda filings: 11 with the exact day known, the rest estimated by month from sources such as ClinicalTrials.gov and company filings. Next up: RHHBY, NRSN, IDYA.

The formal application asking the FDA to approve a new small-molecule drug — the milestone that starts the review clock toward a PDUFA date.

These dates are public. The filterable calendar, alerts, exports and AI research are in the app — free account: the next 7 days and 3 companies you track. Plans →

November 20261

2w
RHHBYNDA Filing

NDA Filing — giredestrant

Nov 30
Source
00%

December 20267

2w
NRSNNDA Filing

NDA Filing — PrimeC

Dec 1
Source
00%
Dec '26
RHHBYNDA Filing

NDA Filing — giredestrant

Dec 2026~
Source
00%
2mo
NRSNNDA Filing

NDA Filing — PrimeC

Dec 31
Source
00%
2mo
IDYANDA Filing

NDA Filing — darovasertib

Dec 31
Source
00%
Dec '26
NVONDA Filing
Phase 3

NDA Filing - etavopivat

Etavopivat
Dec 2026~
Source
00%
Dec '26
RHHBYNDA Filing

NDA Filing

Dec 2026~
Source
00%
2mo
CADLNDA Filing

NDA Filing

Dec 31
Source
00%

January 20273

Jan '27
TLPHNDA Filing

NDA Filing - Niyad

Jan 2027~
Source
00%
2mo
NVSNDA Filing

NDA Filing — Rhapsido

Jan 1
Source
00%
Jan '27
CINGNDA Filing

NDA Filing - CTx-1301

Jan 2027~
Source
00%

February 20271

4mo
BMRNNDA Filing

NDA Filing — VOXZOGO

Feb 28
Source
00%

March 20272

4mo
AQSTNDA Filing

NDA Filing - Anaphylm

Mar 16
Source
00%
5mo
UNCYNDA Filing

NDA Filing - Oxylanthanum Carbonate

Mar 25
Source
00%

May 20271

6mo
AXSMNDA Filing

NDA Filing — AXS-12

May 1
Source
00%

June 20271

8mo
CELCNDA Filing

NDA Filing - gedatolisib

Jun 25
Source
00%
Get NDA Filings Alerts

About NDA Filings

A New Drug Application (NDA) is the formal request a company files to ask the FDA to approve a new small-molecule (chemically synthesized) drug for marketing. It packages the full preclinical and clinical dataset, manufacturing details, and proposed labeling.

Filing is followed by an FDA “acceptance” decision (typically within 60 days), which sets the PDUFA goal date. The submission itself, its acceptance, and any Priority Review designation are each catalysts on the road to approval.

Why NDA Filings matter to investors

An NDA filing de-risks a program: it signals the company believes its Phase 3 package is approvable and starts the countdown to a decision. Acceptance with Priority Review shortens the timeline and is often read as a bullish tell about the strength of the data.

Frequently asked questions

What is an NDA filing?

A New Drug Application is the formal submission asking the FDA to approve a new small-molecule drug. Its acceptance sets the PDUFA date that governs the review.

What is the difference between an NDA and a BLA?

An NDA is for small-molecule (chemically synthesized) drugs; a BLA (Biologics License Application) is for biologics such as antibodies, vaccines and cell/gene therapies. Both follow the PDUFA review framework.

What happens after an NDA is filed?

The FDA decides within ~60 days whether to accept it for review and assigns a PDUFA target action date, optionally granting Priority Review to shorten the timeline.